MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Code Status Video in the Intensive Care Unit: Video Assisted Patient Education

Phase 1

Completed

Conditions: Critical Illness

Interventions: Other: Code Status Video

First Posted Date: 2012-06-01

Last Posted Date: 2016-05-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 208

Registration Number: NCT01610076

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: F-18 FDG
Drug: C-11 PiB

First Posted Date: 2012-05-31

Last Posted Date: 2014-08-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 41

Registration Number: NCT01609335

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis

Phase 1

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Biological: autologous mesenchymal stem cells

First Posted Date: 2012-05-31

Last Posted Date: 2019-09-03

Lead Sponsor: Mayo Clinic

Target Recruit Count: 27

Registration Number: NCT01609283

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: C11 PiB
Drug: F18 Flutametamol

First Posted Date: 2012-05-30

Last Posted Date: 2017-04-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 89

Registration Number: NCT01607476

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer

Phase 2

Terminated

Conditions: Stage II Colon Cancer
Stage III Colon Cancer
Advanced Colorectal Adenomas
Adenocarcinoma of the Colon
Stage I Colon Cancer

Interventions: Drug: defined green tea catechin extract
Other: placebo
Other: questionnaire administration
Other: laboratory biomarker analysis

First Posted Date: 2012-05-25

Last Posted Date: 2017-10-27

Lead Sponsor: Mayo Clinic

Target Recruit Count: 39

Registration Number: NCT01606124

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Hines Veteran's Administration Hospital, Hines, Illinois, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

Phase 4

Terminated

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine fumarate
Drug: Placebo
Procedure: Percutaneous Tibial Nerve Stimulation (PTNS)

First Posted Date: 2012-05-25

Last Posted Date: 2014-02-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 4

Registration Number: NCT01605617

Locations: 🇺🇸
Mayo Clinic in Arizona (MCSB and MCH), Phoenix, Arizona, United States

Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation

Completed

Conditions: Amyloidosis

First Posted Date: 2012-05-25

Last Posted Date: 2014-01-22

Lead Sponsor: Mayo Clinic

Target Recruit Count: 400

Registration Number: NCT01606280

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Family Cancer Literacy to Promote Mammography Screening Among Navajo Women

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Family-based family cancer literacy intervention
Behavioral: Control

First Posted Date: 2012-05-25

Last Posted Date: 2017-12-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 40

Registration Number: NCT01605630

Locations: 🇺🇸
Dine College, Shiprock, New Mexico, United States

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women

Completed

Conditions: Pregnancy
Cancer
Tobacco Use

First Posted Date: 2012-05-25

Last Posted Date: 2017-12-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 150

Registration Number: NCT01605643

Locations: 🇺🇸
Alaska Native Tribal Health Consortium, Anchorage, Alaska, United States

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Stage IIA Breast Cancer
Stage IIC Ovarian Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIB Breast Cancer
Stage IIB Breast Cancer
Stage IIB Ovarian Cancer
Stage IIIA Breast Cancer
Stage IIIB Fallopian Tube Cancer
Stage IIIB Ovarian Cancer

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine

First Posted Date: 2012-05-25

Last Posted Date: 2024-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 24

Registration Number: NCT01606241

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy